InvestSMART

Anteris Technologies Ltd (ASX:AVR)

ALERT: Price-sensitive ASX Announcement for AVR
Current share price for AVR : $13.340 4.43 (49.72%)+
Announcement
Release
23 Jan 2026 9:25AM
Price at Release
$8.910
Full Release
download
Summary
Anteris Technologies Ltd, a global structural heart company, has entered into a material definitive agreement as announced through a Form 8-K filed with the U.S. Securities and Exchange Commission on 22 January 2026. This agreement involves a Stock Purchase Agreement with Covidien Group S.à r.l., a Luxembourg company, wherein Anteris will issue shares of its common stock to Covidien. The transaction is part of a broader strategy to enhance the company's financial position and facilitate the development of its lead product, the DurAVR® THV, designed to treat aortic stenosis. The agreement includes specific terms and registration rights under U.S. securities laws.
Key Points
  • Stock Purchase Agreement with Covidien Group S.à r.l.
  • Issue of common stock shares by Anteris Technologies.
  • Enhancement of financial position for product development.
  • Focus on lead product DurAVR® THV for aortic stenosis treatment.
  • Material definitive agreement disclosed via Form 8-K.
  • Involvement of registration rights under U.S. securities laws.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.